Computational study to investigate Proteus mirabilis proteomes for multi-epitope vaccine construct design
Related Experiment Video
Updated: Aug 18, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Asad Ullah1, Saif Ullah Khan2, Mahboob Ul Haq3
1Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan.
Abstract:
Proteus mirabilis is a gram-negative bacterium particularly known for its unique swarming ability. The swarming gives the bacteria ability to enhance adherence to the catheter surface and epithelium cells of the urethra to cause catheter associated urinary tract infections. P. mirabilis has evolved resistant to antibiotics. Additionally, there is an approved vaccine against P. mirabilis, thus demanding for identification of new vaccine targets. This gram-negative bacterium consists of 19,502 core proteins, out of which 19,063 are redundant proteins and remaining 439 are non-redundant proteins. The non-redundant proteins have 21 proteins present on the cell surface out of which 11 proteins are virulent. Antigenicity analysis predicted only 2 proteins as antigenic (fimbrial biogenesis outer membrane usher protein and ligand-gated channel protein). Four and seven B-cells epitopes were predicted from the former and later proteins, respectively. The predicted B-cells epitopes were used for T- cells epitopes prediction. The predicted epitopes were linked to each other through GPGPG linkers and joined with cholera toxin beta subunit adjuvant. A multi-epitopes vaccine construct consisting of 226 residues was docked with MHC-I, MHC-II and TLR-4. The best docked complex in each case has binding energy of -714.6, -744.6 and -829.5 kcal/mol, respectively. Moreover, the docking results were validated through molecular dynamics simulation and binding free energies estimation. The net energy of -137.2 kcal/mol was calculated for vaccine-MHC-I complex, -133.39 kcal/mol for vaccine-MHC-II and -158.68 kcal/mol for vaccine-TLR-4 complex. The designed vaccine construct could provoke immune responses against targeted pathogen and may be used in experimental testing.Communicated by Ramaswamy H. Sarma.
Insights
This study designed a novel multi-epitope vaccine construct against Proteus mirabilis, a bacterium causing urinary tract infections. The vaccine shows promise for eliciting immune responses and warrants further experimental testing.
Area of Science:
- Microbiology and Immunology
- Vaccine Development
- Bioinformatics
Background:
- Proteus mirabilis causes catheter-associated urinary tract infections due to its swarming motility and antibiotic resistance.
- Existing vaccines necessitate the identification of novel vaccine targets against P. mirabilis.
- Genomic analysis revealed virulent and antigenic proteins on the bacterial cell surface.
Purpose of the Study:
- To design and computationally evaluate a multi-epitope vaccine construct against Proteus mirabilis.
- To identify potential antigenic targets and epitopes for vaccine development.
- To assess the binding affinity and stability of the vaccine construct with immune receptors.
Main Methods:
- Bioinformatic analysis of P. mirabilis proteome to identify surface and virulent proteins.
- Antigenicity and epitope prediction (B-cell and T-cell) using computational tools.
- In silico construction of a multi-epitope vaccine with linkers and adjuvant.
- Molecular docking and molecular dynamics simulations to evaluate vaccine-host interactions.
Main Results:
- Two antigenic proteins were identified, yielding eleven B-cell epitopes and subsequent T-cell epitopes.
- A 226-residue multi-epitope vaccine construct was designed and docked with MHC-I, MHC-II, and TLR-4.
- High binding energies and stable interactions were observed in docking and molecular dynamics simulations, indicating potential immunogenicity.
Conclusions:
- The designed multi-epitope vaccine construct demonstrates potential for inducing immune responses against P. mirabilis.
- Computational findings support further experimental validation and development of this vaccine candidate.
- This study provides a promising strategy for developing new vaccines against antibiotic-resistant P. mirabilis infections.

